Virodhamine

Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases[1][2].

Research Areas >> Neurological Disease

Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor

Virodhamine (50 nM; 72 h) increases adherence, membrane expansion and the size of nucleus[1]. Virodhamine (10-40 μM; 72 h) increases the expression level of CD61 and TRPV1[1]. Virodhamine (72 h) inhibits the cell proliferation of megakaryocyte cells and significantly increases the portion of high ploidy cells as compared to control[1]. Virodhamine significantly increases the protein expression level of CB2 receptorn, ROS production and NAPDH oxidase NOX4 expression in megakaryocytic cells[1]. RT-PCR[1] Cell Line: Megakaryocyte cell line Concentration: 10, 20 and 40 μM Incubation Time: 72 h Result: Dose‐dependently enhanced the expression level of megakaryocytic marker CD61 and the expression of TRPV1 mRNA.

Virodhamine (1-10 mg/kg; i.p. once) repairs the nicotine (0.8 mg/kg) and immobilization stress induced anxiety in vivo[2]. Animal Model: Male ICR mice with nicotine (0.8 mg/kg) and immobilization stress induced anxiety[2] Dosage: 1, 5 and 10 mg/kg Administration: Intraperitoneal injection; 1-10 mg/kg; once Result: Significantly repaired the working memory impairment-like behaviors s at a does of 5 mg/kg and showed significant anxiolytic-like effects against the anxiety-like behaviors at a does of 10 mg/kg.